← All posts
August 27, 2026·13 min read·LBO · Capital Structure · Diligence · EBITDA

The Envision Healthcare LBO: How KKR's $9.9B Physician-Staffing Bet Got Wiped Out by the No Surprises Act

In October 2018 KKR closed a $9.9B take-private of Envision Healthcare — a 10.9x LTM EBITDA multiple on an $8B-revenue physician-staffing platform. Five years later, after a COVID debt exchange, a 2022 uptier priming and a federal statute that repriced the entire business model, KKR walked away with zero in a dual-silo Chapter 11.

The Envision Healthcare LBO is the deal that shows what happens when a peak-multiple healthcare-services buyout meets a federal statute that reprices the entire business model. KKR signed the merger agreement to take Envision private on June 11, 2018 and closed on October 11, 2018 at a total transaction value of approximately $9.9 billion. The purchase price of $46.00 per share represented a 32% premium to Envision's volume-weighted average price for the thirty trading days ended November 1, 2017 — the reference window because the deal talks had been reported in the press starting that day. On the LTM 2017 Adjusted EBITDA of $909 million reported in Envision's 10-K, the deal cleared at 10.9x.

Five years and one month later, on November 3, 2023, KKR walked out of a Chapter 11 confirmation hearing in Houston with a zero. Envision's plan of reorganization split the enterprise into two separate silos — Envision Physician Services (EVPS) and AmSurg — and handed each silo to its own lender group. Blackstone Credit and Brigade Capital took AmSurg. KKR relinquished both.

The interesting thing about the Envision deal is not that it went to zero. Peak-cycle mega-LBOs sometimes do. Toys R Us went to zero. TXU went to zero. Cerberus's Chrysler equity went to zero in twenty-one months. What makes Envision different is that the trigger wasn't a recession or an industry disruption you couldn't see. It was a piece of federal legislation — the No Surprises Act — that had been debated in Congress for years before the buyout closed. Envision's business model was built on the practice the statute was designed to end. The five years between deal close and bankruptcy were spent watching that statute march toward becoming law and then take effect.

What Envision actually was

Envision Healthcare in 2018 was the result of a December 1, 2016 all-stock merger of two publicly-traded specialty healthcare businesses: legacy Envision Healthcare Holdings (which itself had been carved out of Emergency Medical Services and re-IPO'd by Clayton, Dubilier & Rice in 2013) and AmSurg Corp., the largest US operator of ambulatory surgery centers. The merged company took the Envision name and traded as EVHC on the NYSE. It reported approximately $8.5 billion of combined revenue at merger close and became the largest hospital-based physician staffing platform in the country.

By 2017 the combined business had two structurally different halves.

  • Envision Physician Services (EVPS) placed roughly 25,000 physicians and clinicians into hospital emergency rooms, anesthesiology practices, intensive care units, hospitalist services, and women's and children's units under contracts with the hospitals. Revenue was billed to patients and their insurers on a fee-for-service basis, largely through EmCare (emergency medicine) and Sheridan Healthcare (anesthesia). Because emergency physicians and anesthesiologists in a hospital cannot practically negotiate insurance networks patient-by-patient, a meaningful fraction of EVPS revenue historically came from out-of-network patients — where the physician group billed the patient directly for the balance above what insurance paid.
  • AmSurg owned or partnered with roughly 260 ambulatory surgery centers (ASCs) in gastroenterology, ophthalmology and orthopedics. This is an economically straightforward business: physician-partner joint ventures, high-throughput scheduled procedures, network contracts negotiated at the ASC level.

Envision's 2017 10-K reported $7.8 billion in revenue and $909 million in Adjusted EBITDA. Physician services generated about 81% of core revenues; ambulatory surgery ~19%. In terms of quality of earnings, the ambulatory surgery business was the healthier half and the hospital-based physician business was the leveraged half. That distinction — buried in the segment footnotes at signing — is what allowed the eventual Chapter 11 to be structured as a clean two-silo split.

The deal, in numbers

Envision had been publicly rumored as a strategic-review target through late 2017 after activist investor Corvex Management (Keith Meister) took a large position and pushed the board to explore a sale. KKR emerged as the winning bidder in a formal process. The definitive merger agreement was signed on June 11, 2018 and closed just four months later on October 11, 2018.

Envision LBO — closing terms, October 11, 2018Amount
Announcement dateJun 11, 2018
Close dateOct 11, 2018
Per-share consideration$46.00 cash
Premium to Nov 1, 2017 30-day VWAP32%
Total transaction value$9.9B
Equity purchase price (~119M shares)~$5.5B
LTM 2017 Adjusted EBITDA$909M
EV / LTM Adjusted EBITDA10.9x
EV / 2018E Adjusted EBITDA (per proxy)10.1x
New debt raised at close~$7.0B
Sponsor equity contribution (implied)~$2.9B

The $7 billion of new debt raised at close broke out into a $5.3 billion first-lien term loan due October 2025 alongside 8.75% senior unsecured notes due October 2026 and other unsecured tranches. The senior unsecured coupon of 8.75% for an investment-grade-adjacent healthcare-services borrower in 2018 is worth flagging on its own: the market was already pricing in real credit risk at close.

A 10.9x entry multiple on a physician-staffing business with the segment mix Envision reported was aggressive but not obviously mispriced against 2018 comparables — HCA traded around 9-10x forward EBITDA, and specialty-services roll-ups traded higher. What the multiple did not capture was the structural political risk sitting inside the emergency-medicine revenue line. That risk had a name and it had been sitting in Congress since 2016: balance-billing reform.

What "surprise billing" actually was, and why it mattered here

Before the No Surprises Act, when a patient went to an in-network hospital and received emergency-room care from an out-of-network physician group — the ER doctor was employed by a contracted staffing company like EVPS, not the hospital itself — the physician group could bill the patient directly for any amount above what the patient's insurer paid. The patient often had no way to select an in-network ER doctor at the moment of care. This is what came to be called "surprise billing" or "balance billing."

For physician-staffing companies, out-of-network status was not accidental. It was often deliberate. If EVPS could not reach an acceptable in-network contract rate with a payor, going out-of-network meant it could bill patients at a higher usual-and-customary rate — a rate that in many markets was materially above negotiated in-network rates. Multiple academic studies of hospital-based physician billing (see Cooper et al., Yale School of Management, 2017-2020) found that private-equity-owned physician groups were significantly more likely to be out-of-network than physician-owned practices and that they generated higher effective per-encounter revenue as a result.

That practice was the target of federal legislation as early as the 116th Congress. Bipartisan discussion drafts circulated in 2019, industry lobbying pushed back for two years, and a compromise passed in December 2020 as part of the omnibus year-end spending bill. Signed into law on December 27, 2020, the No Surprises Act took effect on January 1, 2022.

The statute did three things that directly hit Envision's revenue model.

  1. Prohibited out-of-network billing to patients for emergency services delivered at in-network facilities.
  2. Prohibited out-of-network billing for non-emergency services delivered by out-of-network providers at in-network facilities in most cases (anesthesia, radiology, pathology, etc.).
  3. Established an Independent Dispute Resolution (IDR) process in which the out-of-network provider and the insurer submit competing rates to a certified arbitrator, who picks one.

The provider community argued vigorously — including via extensive litigation, some of it successful — that the interim final rule implementing the IDR process favored insurers by benchmarking to the payor's Qualifying Payment Amount. But the underlying structural fact was that the practice of balance-billing patients at usual-and-customary rates was over. The reference point for out-of-network compensation was now an arbitrator's determination, not what the physician group chose to bill.

For an emergency-medicine business owned by KKR at 10.9x EBITDA, that mattered.

The 2020 COVID exchange — the first crack

COVID hit Envision hard in the second quarter of 2020. Elective surgery volumes collapsed as hospitals postponed non-emergency procedures. Emergency room visits fell as patients stayed home. AmSurg's ambulatory surgery centers, which depend on scheduled procedure volume, ran at deeply reduced utilization for several months. Envision took federal Provider Relief Fund grants and other CARES Act funding to bridge the gap, but the leveraged balance sheet gave management no runway to wait for volumes to recover.

On May 1, 2020, Envision announced the completion of a debt exchange in which approximately $724 million of senior unsecured notes due 2026 and floating-rate private-placement notes were exchanged for approximately $395 million of new first-lien senior secured term loans due 2025. In headline terms it was a de-leveraging: face debt reduced by roughly $329 million and interest expense reduced. Structurally it was the first repricing of the LBO capital stack, and it moved unsecured creditors into a smaller secured position at a discount to par.

The 2020 exchange bought approximately two years of runway. It did not address either of the two binding constraints — the 2025-2026 debt-maturity wall or the January 1, 2022 effective date of the No Surprises Act. It was a COVID bridge, not a solution.

The 2022 uptier priming — the second crack

By early 2022 the No Surprises Act had taken effect, UnitedHealthcare had already pushed Envision out-of-network in January 2021 (a move that eventually led to a federal lawsuit in Tennessee in September 2022 and, separately, a March 30, 2023 arbitration award of $91.2 million to Envision for 2017-2018 in-network underpayments), and elective volumes were recovering but not to pre-COVID levels. Envision's operating cash flow could not service the existing debt stack.

In April 2022 Envision executed what is now taught in restructuring casebooks as a canonical uptier priming transaction. Lenders holding approximately 96% of the existing first-lien term loans agreed to exchange their positions for a new four-tranche first-lien facility, structured as roughly $300 million first-out, $2.2 billion second-out, $1.0 billion third-out, and $189 million fourth-out. Non-participating lenders — the 4% who declined to consent — were left in an unmodified position that was now structurally junior to all four new tranches.

The dynamic was straightforward: Envision needed to raise fresh liquidity to survive, and lenders demanded priority for the new money in exchange for providing it. Existing lenders who consented were promoted into the first-out and second-out tranches, effectively taking priority over holdouts. This is the same priming loan mechanic that has become the dominant liability-management tool in stressed sponsor deals over the last decade.

The uptier bought maybe twelve months. It did nothing to fix the operating business.

The March 2023 arbitration win — a $91.2M rounding error

On March 30, 2023, an arbitration panel awarded Envision $91.2 million in its dispute with UnitedHealthcare over 2017-2018 in-network reimbursement underpayments. The judgment was widely reported when Envision disclosed it in June 2023. It confirmed Envision's litigation posture — that UnitedHealthcare had unilaterally reduced reimbursement rates below the network agreement — but $91.2 million against a $7.7 billion debt stack is a rounding error. It was announced after the Chapter 11 filing had already been made.

The larger post-No-Surprises-Act arbitration exposure was still open at that point and would eventually become a separate line of dispute between the reorganized Envision entities and the major national payors.

The May 2023 Chapter 11

Envision filed voluntary Chapter 11 petitions in the United States Bankruptcy Court for the Southern District of Texas on May 15, 2023, reporting approximately $7.7 billion of debt obligations. The petitions were filed simultaneously with a Restructuring Support Agreement supported by holders of approximately 60% of the debt. Notably there was no debtor-in-possession financing; the case ran on consensual use of cash collateral throughout.

The structural design of the plan was the interesting piece. Rather than reorganize Envision as a single going concern, the plan created two separate silos:

  • Envision Physician Services (EVPS) — hospital-based physician staffing, the segment most exposed to the No Surprises Act. Its lenders (holders of the EVPS-level term loan tranches created in the 2022 uptier and of the $938.9 million of remaining unsecured notes) took the equity in the reorganized EVPS.
  • AmSurg — the ~250 ambulatory surgery centers, a structurally healthier business with a separate revenue stream. Its lenders — a different creditor group with Blackstone Credit and Brigade Capital reported among them — took the equity in the reorganized AmSurg.

The two silos had already been operationally and financially separated in advance of the filing so that the dual-silo plan could be executed cleanly. The plans of reorganization for both silos were confirmed on October 11, 2023 — exactly five years to the day after KKR had closed on Envision. Both entities emerged from bankruptcy on November 3, 2023, approximately 172 days after filing. In aggregate the restructuring eliminated roughly $7 billion of debt across the two silos.

KKR received nothing. The equity in both post-emergence entities went to the pre-petition lender groups. That included KKR's initial ~$2.9 billion sponsor equity contribution plus whatever follow-on capital it or its co-investors had committed during the 2020 and 2022 liability-management transactions — figures that KKR has not disclosed separately.

The lesson, and it isn't about leverage

The temptation with a deal like Envision is to blame the leverage — 10.9x EBITDA on a healthcare-services business is aggressive, and $7 billion of new debt on $909 million of Adjusted EBITDA implies interest coverage that had almost no room for a business shock. That framing is technically right and analytically shallow.

The deeper problem is that a specific policy risk was observable to any diligent underwriter in the summer of 2018 and it was not stress-tested in the model. Balance-billing reform had been proposed federally by 2016, was actively debated at the state level in New York, California and several other markets by 2017, and had the political attributes of an eventual bipartisan vote — voters hated surprise bills, insurers wanted the practice ended, and only the physician-staffing industry (a diffuse lobby with a public-relations problem) was actively opposing it. When you underwrite a business whose EBITDA depends on a legal practice being political roadkill within five years, you have to model the alternative case where the practice ends. That is not a stress test — it is the base case for the second half of the hold.

The other lesson is about payor concentration. UnitedHealthcare alone was capable of moving Envision out-of-network in January 2021 — a full year before the No Surprises Act took effect — and materially damaging the P&L. Any concentrated-payor healthcare-services business carries this feature. In diligence, decomposing revenue by payor and stress-testing each concentrated relationship to a unilateral rate cut is a first-order exercise. It was not, apparently, done at a level of severity commensurate with the actual risk.

Compare this to the HCA LBO, which closed in November 2006 at a comparable multiple. HCA was hospitals — capital-intensive, reimbursed largely by Medicare and commercial payors at contractually negotiated rates, and with a business model that did not depend on a specific billing practice that was politically vulnerable. HCA rode out the global financial crisis, executed $4.25 billion in dividend recaps before its 2011 IPO, and produced one of the best mega-LBO exits of the era. Same industry vertical at the sector level. Radically different structural exposure at the business-model level.

Practical takeaway

If you are underwriting a leveraged buyout of a services business whose EBITDA depends on any specific billing, contracting, or regulatory practice — surprise billing, No Surprises Act arbitration outcomes, drug rebates, PBM spread pricing, out-of-network reimbursement for anything — you have to model the case where that practice ends. Not as a sensitivity. As one of your three or four base cases. Then look at what your debt capacity is against that case's EBITDA, not against the LTM.

The 2018 Envision underwriting assumed a structural continuation of the pre-No-Surprises-Act billing regime. That assumption was falsifiable in real time by anyone reading Congressional Budget Office scoring of surprise-billing bills. It was falsified by legislation in December 2020, twenty-six months after close, and by regulation on January 1, 2022. The five years between close and Chapter 11 were the time it took the underlying operating business to metabolize a policy change that was already in flight when KKR signed the merger agreement.

If you want to model an LBO with adjustable leverage assumptions, EBITDA scenarios, and payor-concentration stress cases, the All-in-One PE Model is built for exactly that kind of underwriting workflow — 26 worksheets covering the full LBO capital structure, returns waterfall, and diligence pack. See the sheet preview for the full worksheet index.

Sources:

Use the same model on every deal.

26 fully-integrated worksheets. LBO + DCF + Comps + 3-statement + debt schedules + EVA. One-time download.

100% money-back if you find any error
Keep reading
LBO
The Avaya LBO: How TPG and Silver Lake's $8.3B Enterprise Telecom Bet Filed Chapter 11 Twice in Six Years
In October 2007 TPG and Silver Lake took Avaya private for $8.3B at $17.50 per share. Nine years later the company filed Chapter 11 and wiped the sponsor equity. Five years after that, the reorganized company filed Chapter 11 again and wiped the public shareholders. Inside the slow-motion LBO bust.
LBO
The Biomet LBO: How Four Sponsors Put $5.2B of Equity Into a Peak-Cycle Medical Device Buyout — and Waited Eight Years to Get It Back
In 2007 Blackstone, Goldman, KKR and TPG jointly took Biomet private for $11.4B — the biggest medical device LBO ever and the archetypal four-sponsor club deal of the peak cycle. Nearly eight years, a 2013 markdown and a stock-and-cash merger with Zimmer later, the sponsors got their money back and modestly more.